The safety and feasibility of the "pan-gate theory" in laparoscopic liver resection through laennec's approach combined with "regional hepatic inflow occlusion" for hepatocellular carcinoma

采用 Laennec 入路联合“区域性肝脏入血阻断”进行腹腔镜肝切除术治疗肝细胞癌的“全闸门理论”的安全性和可行性

阅读:1

Abstract

BACKGROUND: The "pan-gate theory", an innovative extension of the "gate theory," optimizes Laennec's approach in laparoscopic liver resection (LLR) by increasing adaptability to anatomical variations and facilitating rapid isolation of the target hepatic pedicle for precise regional inflow occlusion. This study evaluated the safety and feasibility of the "pan-gate theory" in LLR for hepatocellular carcinoma (HCC), with a focus on technical advantages and postoperative outcomes. METHODS: This was a single-arm retrospective study of 48 HCC patients who underwent LLR via the pan-gate Theory (June 2022-September 2023). The primary outcomes were operative time and estimated blood loss (EBL). The secondary outcomes included complications, postoperative hospital stay (PHS), and disease-free survival (DFS). The surgical procedure, guided by the pan-gate theory, included entering Laennec's capsule-Glissonean sheath through the red-yellow demarcation line for regional hepatic inflow occlusion, whereas Laennec's approach is utilized for parenchymal and hepatic vein management. RESULTS: The median operative time was 164 (110-217) min, and the EBL was 100 (50-200) mL. All patients achieved R0 resection without conversion to open surgery. Postoperative complications included bile leakage (Grade B) in 7 patients and controlled bleeding in 1 patient. The median PHS was 7.5 (5.6-10.4) days. The one-year DFS rate was 87.5%, with zero mortality. Postoperative quality of life (EORTC QLQ-C30) improved across dimensions. CONCLUSION: Pan-gate theory demonstrates the safety and feasibility of LLR for the treatment of HCC, indicating that LLR is superior in terms of anatomical variation management. It results in short operative times, minimal blood loss, and few complications, with favourable long-term outcomes. Multicenter studies are needed to validate these findings and optimize their clinical application.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。